Diphtheria Toxin/Human B-Cell Activating Factor Fusion Protein Kills Human Acute Lymphoblastic Leukemia BALL-1 Cells: An Experimental Study

Xin-pu Gao1, Zheng-min Liu2, Yu-lian Jiao1, Bin Cui1, Yue-ting Zhu1, Jie Zhang1, Lai-cheng Wang1, Yue-ran Zhao1*

1Central Laboratory, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
2Laboratory Department of Jinan Blood Station, Blood Center of Shandong Province, Jinan 250001, China

10.1007/s11670-012-0238-0
©Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg 2012

ABSTRACT

Objective: This study aimed to express a fusion protein of diphtheria toxin and human B cell-activating factor (DT388sBAFF) in Escherichia coli (E. coli) and investigate its activity in human B-lineage acute lymphoblastic leukemia 1 cells (BALL-1).

Methods: A fragment of DT388sBAFF fusion gene was separated from plasmid pUC57-DT388sBAFF digested with Nde I and Xho I, and inserted into the expression vector pCold II digested with the same enzymes. Recombinants were screened by the colony polymerase chain reaction (PCR) and restriction map. The recombinant expression vector was transformed into BL21 and its expression was induced by isopropyl β-D-1-thiogalactopyranoside (IPTG). The recombinant protein was identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot, and then purified by Ni2+-NTA affinity chromatography. The expression level of B cell-activating factor receptor (BAFF-R) on BALL-1 cells was assessed by real-time PCR. The receptor binding capacity of recombinant protein was determined by cell fluorescent assay. The specific cytotoxicity of recombinant protein on BALL-1 cells was detected by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay.

Results: The expression level of recombinant protein was 50% of total bacterial proteins in E. coli, and the recombinant protein could bind to BAFF-R-positive BALL-1 cells and thereby produce a cytotoxic effect on the cells.

Conclusion: The fusion protein expression vector DT388sBAFF was successfully constructed and the recombinant protein with selective cytotoxicity against BALL-1 cells was obtained, providing foundation for further study of the therapy of human B-lineage acute lymphoblastic leukemia.

Key words: B cell-activating factor; B-lineage acute lymphoblastic leukemia; Diphtheria toxin; Fusion protein

INTRODUCTION

Immunotoxin is an artificial hybrid molecule with a targeted killing ability[1], consisting of a targeting moiety and a toxic payload. The targeting moiety falls into two categories: one is monoclonal antibody; the other is certain receptor or ligand with important physiological functions. The toxic payload is usually a protein toxin, either plant or bacterial. Immunotoxin commonly contains toxins such as diphtheria toxin and pseudomonas exotoxin[2]. Immunotoxins targeting hematological malignancies and solid tumors have been additionally demonstrated with excellent clinical activity[3], representing a second revolution in antibody-mediated cancer therapy[4].

B cell-activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS), TNF- and APOL-related leukocyte expressed ligand 1 (TALL-1), or TNF homolog that activates apoptosis, NKFB, and JNK (THANK), is a member of tumor necrosis factor (TNF) superfamily[5,6] and is expressed on the surface of monocytes, dendritic cells (DC), neutrophils, stromal cells, activated T cells, malignant B cells and epithelial cells[7,8]. BAFF can bind to three different receptors,
BAFF receptor (BAFF-R), transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and B cell maturation protein (BCMA), which are expressed seperately at various times during B cell ontogeny[9]. BAFF-R specifically expresses on more mature B cells, starting at the T1 transitional B cell stage[7]. Nevertheless, a recent research [9] presented evidence that the BAFF-R is universally expressed on B-lineage acute lymphoblastic leukemia (ALL) cells which develop by transformation of normal B-cell progenitors. Other studies have demonstrated that the fusion protein of BAFF and gelonin, a plant toxin, had the killing effects against BAFF-R (+) B lymphoma cells[10, 11].

To investigate the human B cell leukemia BALL-1 cell-targeting effect of BAFF/diphtheria toxin fusion protein DT388sBAFF and the feasibility of its clinical applications, in this study, we expressed DT388sBAFF in *Escherichia coli* (*E. coli*), purified the recombinant protein and investigated its biological activity in target BAFF-R (+) BALL-1 cells.

**MATERIALS AND METHODS**

**Materials**

The whole gene synthesis of pUC57-DT388sBAFF was carried out by Nanjing Genscript Biotechnology (Nanjing, China). The *pcold* II vector was constructed by the central laboratory of the Provincial Hospital Affiliated to Shandong University. The polymerase chain reaction (PCR) reagents, RNA isolation kit, and real-time PCR kits were purchased from Takara Biotechnology (Dalian, China). The DNA marker was purchased from Tiangen Biotech (Beijing, China). T4 DNA ligase, restriction enzymes *Nde* I, *Xho* I, protein marker and gel extraction kit were products of MBI Fermentas (Shenzhen, China). *E. coli* DH5α and BL21 were purchased from TransGen Biotech (Beijing, China). The plasmid extraction kit was prepared by the central laboratory of the Provincial Hospital Affiliated to Shandong University. Yeast extract, peptone and agar were purchased from Oxoid (Basingstoke, UK). The protein quantification kit was purchased from Fermentas (Shenzhen, China). *E. coli* BL21. Isolated colonies were selected and cultured to logarithmic phase. Inducer IPTG was then added to a final concentration of 1 mmol/L, followed by inducing at 15°C for 24 h. The expression level of the target protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The recombinant protein was identified by Western blot with anti-BAFF and polyclonal anti-His-Tag.

**Expression and Identification of the Recombinant Protein**

The positive recombinant expression vector *pcold* II/DT388sBAFF was transformed into competent strain *E. coli* BL21. Isolated colonies were selected and cultured to logarithmic phase. Inducer IPTG was then added to a final concentration of 1 mmol/L, followed by inducing at 15°C for 24 h. The expression level of the target protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The recombinant protein was identified by Western blot with anti-BAFF and polyclonal anti-His-Tag.

**Protein Purification**

In accordance with the instructions of QIAgenes *E. coli* Handbook, the fusion protein was purified with the non-denaturing method. The ultrasonic supernatant of recombinant strain was fully integrated with Ni²⁺-NTA column at 4°C for 1 h. After washing and elution, imidazole and other small molecules were removed by dialysis, and the recombinant protein was detected by SDS-PAGE.

**Detection of BAFF Receptors Expression**

The mRNA expression of human BAFF receptors (BAFF-R, TACI and BCMA) in BALL-1, Hmy2.CIR and U937 cell lines was assessed by real-time PCR[12]. The total mRNA of these cell lines was isolated by an RNAiso Plus kit (Takara, Dalian, China). The primers of BAFF-R, TACI and BCMA were as follows: BAFF-R: 5′-GGAGGAGGCCAGGACCACG-3′ (sense) and 5′-AAG

---

---
Reference Dye II, 2.0 μl reverse primer, 0.8 μl 0.4 μl Hmy2.CIR cells and U937 cells (5 μl). Firstly, in the logarithmic phase, BALL-1 cells, DT388sBAFF on human BALL-1 cells and control cells. The killing effect of the recombinant protein toxin was detected through the same procedure as aforesaid. Cytotoxicity Experiment. The cloning vector pUCS7-DT388sBAFF was double digested with Nde I and Xho I, and the targeting fusion gene fragment, diphtheria toxin-human BAFF gene, was isolated. Agarose gel electrophoresis showed the fragment at 1,629 bp, which was consistent with the target gene (Figure 1). The isolated target gene fragment was inserted into the corresponding site of pcold II to construct the recombinant expression vector which was transformed into E. coli DH5α and then identified by colony PCR (Figure 2). The recombinant plasmid DNA was confirmed by the double restriction digestion analysis (Figure 3), and its sequencing result was identical with the optimal target gene sequence. Construction of Recombinant Expression Vector. SDS-PAGE showed that pcold II-DT388sBAFF was positively induced, and a distinct protein band with the relative molecular mass of 58.4 kD was visible, which was consistent with the expected protein size (Figure 4). Image analysis demonstrated that the target protein accounted for about 50% of the total bacterial proteins. Expression of Recombinant Protein. The recombinant protein was identified by Western blot with anti-BAFF and polyclonal anti-His-Tag. The results showed that the two antibodies reacted specifically with the target protein, indicating that the recombinant protein was the specific DT388sBAFF fusion protein (Figure 5).

**RESULTS**

**Construction of Recombinant Expression Vector**

**Expression of Recombinant Protein**

**Identification of Recombinant Protein**

www.cjcrbj.com
Purification of the Recombinant Protein

Recombinant bacterial lysate, ultrasonic supernatant and ultrasonic inclusion bodies were analyzed by SDS-PAGE, showing that the recombinant protein was present in the supernatant and suggesting that the expression of DT388sBAFF was in a soluble form in strain cytoplasm. After purification by Ni²⁺-NTA affinity chromatography, the purity of the recombinant protein DT388sBAFF was more than 90% (Figure 6).

Expression of BAFF-R mRNA

The mRNA expression of BAFF receptors (BAFF-R, TACI and BCMA) in the three cell lines was examined by real-time PCR. Hmy2.CIR and U937 cells showed no or undetectable mRNA expression of BAFF receptors (Figure 7).

Biological Activity of Recombinant Protein

Detection of the fluorescent-labeled recombinant protein showed its ability of binding to cell surface receptors. Under the inverted fluorescence microscope, strong green fluorescence could be observed in BALL-1 and Hmy2.CIR cells, but the negative control group did not show fluorescence in U937 cells (Figure 8), indicating that there was a specific binding ability between the recombinant protein and surface receptors on BALL-1 and Hmy2.CIR cells. Whereas the BALL-1, Hmy2.CIR and U937 cells with fluorescent-labeled free diphtheria toxin did show fluorescence not all. Cytotoxicity assay demonstrated a killing effect of the
recombinant protein on BALL-1 and Hmy2.CIR cells. The results showed a strong inhibitory effect in a dose-dependent manner, meaning that such inhibitory effect increased with higher protein concentration and was higher in Hmy2.CIR cells than in BALL-1 cells. The negative control groups BALL-1 and Hmy2.CIR with free diphtheria toxin and U937 cells did not exhibit such inhibitory effect (Figure 9).

DISCUSSION

Immunotoxin has both specific recognition and anti-toxin function. Therefore, they have been extensively researched for applications in cancer, autoimmune diseases, transplant rejection and many other disorders. Some drugs have been approved by the US Food and Drug Administration for production, whereas many others are in pre-clinical or clinical studies[14]. Carried into the target cells by the targeting protein of immunotoxin, the toxin inhibits protein synthesis in these cells and thereby causes the death of tumor cells, achieving a specific killing effect without damage to normal tissues[15, 16].

In 1990s, the recombinant immunotoxin technology emerged with the development of molecular biology techniques[17-19]. In this technology, the encoding gene of a toxin and the ligand gene of a specific tumor cell surface molecule are fused into a recombinant plasmid. After expression in prokaryotic or eukaryotic cells and purification, a new type of immunotoxin which is stable, uniform, more permeable, less immunogenic, less molecularly weighted and easy for large-scale production is obtained. The immunotoxin technology brings a new hope to the treatment of autoimmune diseases, as immunotoxins play important roles in the immune process of killing target cells.

BAFF is a type II transmembrane protein with N terminal intracellular domain, absent signal peptide, and C terminal extracellular domain which is highly homologous with TNF- and APOL-related leukocyte expressed ligand 2 (APRIL) of the TNF superfamily[20]. BAFF exists in two forms: membrane-bound and soluble ligands. The former consists of 285 amino acids, among which amino acid 47 to 73 are transmembrane domain and 74 to 285 are the extracellular region which
is formed by the extracellular domain falling off under the action of the protease and has the functions of binding and activating B cells. Studies have shown that BAFF has three receptors: BCMA, TACI and BAFF-R (BR3), all of which are expressed mainly on B cells. BAFF and its receptor BAFF-R are important for survival and growth of mature normal B cells.

BAFF and its receptor BAFF-R are important for survival and growth of mature normal B cells. BAFF has three receptors: BCMA, TACI and BAFF-R (BR3), all of which are expressed mainly on B cells. BAFF and its receptor BAFF-R are important for survival and growth of mature normal B cells.

B-lineage acute lymphoblastic leukemia (ALL) originates from transformation of progenitor (pre-B) cells, and it is generally believed that BAFF-R is not expressed on pre-B cells. But a recent study[9] had found that BAFF-R is a pre-B leukemia-specific cell surface antigen and thus opened the possibility of using the receptor-mediated pathway to deliver a certain fusion toxin to ALL cells as an adjuvant therapeutic strategy. Another research[21] had demonstrated a diphtheria toxin interleukin-3 fusion protein [DT(388)IL3] can improve the effectiveness of tyrosine kinase inhibitors (TKIs), such as imatinib and dasatinib, against Ph+ leukemia. Studies have shown that the action of the protease and has the functions of binding and activating B cells. Studies have shown that BAFF has three receptors: BCMA, TACI and BAFF-R (BR3), all of which are expressed mainly on B cells. BAFF and its receptor BAFF-R are important for survival and growth of mature normal B cells.

The immunotoxin designed in this research comprised smBAFF, the mutant of soluble BAFF in which amino acid 217 to 224 were deleted, as the targeting moiety which was necessary to maintain the activation of BAFF[22]. The mutant retained the activity of binding to receptors, whereas the B-cell proliferation activity was significantly reduced, thus eliminating the potential side effects of the immunotoxin stimulated B-cell proliferation. In this study, the active fragment of diphtheria toxin DT388, a cytotoxic molecule and BAFF, a targeting molecule, between which a flexible linker (GGGGS) was inserted, could effectively maintain protein conformation at both ends to facilitate their respective functions. To improve the expression level of fusion protein in E. coli, the codon of target gene and the mRNA secondary structure had been optimized to enhance the expression of recombinant immunotoxins. The target protein obtained from the genetically engineered strain accounted for about 50% of the bacterial proteins.

Biological activity studies have shown that the DT388sBAFF fusion protein possessed the receptor-specific binding activity and targeted cytotoxicity to BALL-1 and Hmy2.CIR cells. Among BAFF receptors, only BAFF-R was detected to express highly on both BALL-1 and Hmy2.CIR cells. TACI and BCMA showed weakly or undetectable mRNA on BALL-1 cells. This finding indicates that BAFF-R plays a key role in the inhibitory effect, and established an experimental foundation for its application in the biological treatment of B-lineage acute lymphoblastic leukemia.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

REFERENCES


Figure 9. Specific cytotoxicity of recombinant protein on B cell line. The figure showed a strong inhibitory effect in a dose-dependent manner, suggesting that such inhibitory effect increased with increased protein concentration and Hmy2.CIR cells were more remarkable than BALL-1 cells (P<0.05). The negative control group BAFF-R (-) U937 cells did not exhibit such inhibitory effect (P<0.05); and BALL-1, Hmy2.CIR and U937 cells with free diphtheria toxin did not also show such inhibitory effect (P<0.05).


